The immunotherapy for head and neck cancer

郭　晔

doi:10.19401/j.cnki.1007-3639.2017.06.010

您当前的位置：

首页 >

文章列表页 >

The immunotherapy for head and neck cancer

更新时间：2025-12-31

- The immunotherapy for head and neck cancer
- China Oncology Vol. 27, Issue 6, Pages: 459-462(2017)
- 作者机构：
  
  复旦大学附属肿瘤医院肿瘤内科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2017.06.010
  CLC：
- Published Online：26 July 2017，
  
  Published：26 July 2017
- 稿件说明：
移动端阅览
郭　晔. 头颈部肿瘤的免疫治疗[J]. 中国癌症杂志, 2017, 27(6): 459-462.

郭　晔. The immunotherapy for head and neck cancer[J]. China Oncology, 2017, 27(6): 459-462.
郭　晔. 头颈部肿瘤的免疫治疗[J]. 中国癌症杂志, 2017, 27(6): 459-462. DOI： 10.19401/j.cnki.1007-3639.2017.06.010.

郭　晔. The immunotherapy for head and neck cancer[J]. China Oncology, 2017, 27(6): 459-462. DOI： 10.19401/j.cnki.1007-3639.2017.06.010.

摘要

头颈部鳞癌(head and neck squamous cell carcinoma，HNSCC)是头颈部肿瘤的常见类型，其治疗水平有待提高。作为一种具有高度免疫缺陷的肿瘤，HNSCC主要机制包括免疫耐受的导入、局部的免疫逃逸和T细胞信号的破坏。免疫检查点是T细胞功能的重要决定因素，目前针对程序性细胞死亡1受体(programmed cell death 1，PD-1)的抑制剂得到了快速的发展。作为人源化的抗PD-1单克隆抗体，pembrolizumab和nivolumab均显示出针对复发或转移性HNSCC具有一定的解救治疗作用，进一步的研究值得期待。

Abstract

The predominant type of head and neck cancer is head and neck squamous cell carcinoma (HNSCC)

which needs more effective treatment. As a highly immunosuppressive malignancy

HNSCC has 3 major mechanisms including induction of immune tolerance

local immune evasion

and disruption of T-cell signaling. Immune checkpoint plays a critical role in the function of T-cell and rapid development has been achieved by inhibiting programmed cell death 1 (PD-1). As anti-PD1 humanized monoclonal antibodies

pembrolizumab and nivolumab have proven to be effective in the salvage treatment for recurrent or metastatic HNSCC

further investigation is awaited.

关键词

Keywords

references

Views

1711

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

MDT consensus on immunotherapy for locally advanced head and neck squamous cell carcinoma (2025 edition)

Advances and future perspectives of neoadjuvant immunotherapy in colorectal cancer

Application progress of oncolytic virus combined with immunotherapy in the treatment of malignant tumors

Current status and future directions of immunotherapy for advanced non-small cell lung cancer

Advances in immunotherapy for metastatic renal cancer

Related Author

Ye GUO

Chaosu HU

Chenping ZHANG

Yuyang ZHANG

Qian LIU

Yingyun LIANG

Jianhua CHEN

Chunxia SU

Related Institution

Committee of Head and Neck Cancer, Chinese Society of Clinical Oncology

Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Shanghai Lung Tumor Clinical Medical Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University

Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University

AI问答

⁰